Good move by Lilly
In move that is long overdue Lilly (NYSE:LLY) announced this morning a color differentiation system for their U-100 insulin products. According to the company “With color differentiation, the redesigned labeling can help patients, health care providers and pharmacists accurately identify the insulin that has been prescribed.”
Diabetic Investor applauds this move and sees this as just one more example of Lilly’s recommitment to their insulin franchise. Diabetic Investor hopes Novo Nordisk (NYSE:NVO) and Sanofi-Aventis (NYSE:SNY) follow Lilly’s lead.